
Plexium Inc, a developer of protein degrading therapeutics directed towards historically challenging drug targets, has secured $35 million in financing. Lux Capital and Pivotal BioVentures led the round.
Source: Press Release
Plexium Inc, a developer of protein degrading therapeutics directed towards historically challenging drug targets, has secured $35 million in financing.
Plexium Inc, a developer of protein degrading therapeutics directed towards historically challenging drug targets, has secured $35 million in financing. Lux Capital and Pivotal BioVentures led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination